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ABSTRACT
A variety of diseases lead to degeneration of retinal ganglion cells (RGCs) and their axons within
the optic nerve resulting in loss of visual function. Although current therapies may delay RGC
loss, they do not restore visual function or completely halt disease progression. Regenerative
medicine has recently focused on stem cell therapy for both neuroprotective and regenerative
purposes. However, signiﬁcant problems remain to be addressed, such as the long-term impact
of reactive gliosis occurring in the host retina in response to transplanted stem cells. The aim of
this work was to investigate retinal glial responses to intravitreally transplanted bone marrow
mesenchymal stem cells (BM-MSCs) to help identify factors able to modulate graft-induced reac-
tive gliosis. We found in vivo that intravitreal BM-MSC transplantation is associated with gliosis-
mediated retinal folding, upregulation of intermediate ﬁlaments, and recruitment of macro-
phages. These responses were accompanied by signiﬁcant JAK/STAT3 and MAPK (ERK1/2 and
JNK) cascade activation in retinal Muller glia. Lipocalin-2 (Lcn-2) was identiﬁed as a potential
new indicator of graft-induced reactive gliosis. Pharmacological inhibition of STAT3 in BM-MSC
cocultured retinal explants successfully reduced glial ﬁbrillary acidic protein expression in retinal
Muller glia and increased BM-MSC retinal engraftment. Inhibition of stem cell-induced reactive
gliosis is critical for successful transplantation-based strategies for neuroprotection, replace-
ment, and regeneration of the optic nerve. STEM CELLS 2015;33:3006–3016
SIGNIFICANCE STATEMENT
Over the last decade there has been considerable interest in the potential use of stem cell
therapy for protective, regenerative and cell replacement purposes in a variety of neurodege-
nerative conditions of the eye and brain. However a major barrier to overcome for clinical
translational is the aggressive reactive gliosis which the host tissue undergoes in response to
grafted stem cells in some systems. We dissected signalling pathways behind graft induced
reactive gliosis and proposed a molecular mechanism orchestrating this response, in the con-
text of MSC transplantation for optic nerve protection and repair. As reactive gliosis is a poten-
tial obstacle to stem cell-based strategies throughout the CNS, our finding may have
considerable relevance in the field of stem cell therapy for CNS protection and repair.
INTRODUCTION
Retinal ganglion cells (RGCs) are the output
cells of the retina and RGC axons transmit vis-
ual information from the eye to the brain via
the optic nerve. The optic nerve can be
affected by many pathological conditions,
including traumatic, ischemic, inﬂammatory,
and degenerative disorders [1]. Different etiol-
ogies may result in progressive and irreversible
loss of RGCs [1] resulting in partial or com-
plete visual loss. Glaucoma, the leading cause
of irreversible blindness worldwide, is a degen-
erative condition characterized by the selective
loss of RGCs. We have previously shown the
feasibility of protecting RGCs using bone mar-
row mesenchymal stem cells (BM-MSCs) in a
rat model of glaucoma [2, 3]. However, one of
the unaddressed obstacles is the gliotic
response that astrocytes and Muller glia (non-
neuronal support cells within the retina)
exhibit in response to grafted cells [4–6]. In
retinal cell neuroprotection and replacement
therapy, the glial response to the donor cell
graft is an important barrier to overcome in
order to enhance synaptic plasticity and axonal
remodeling of surviving neurons as well as
integration of a variety of donor cell types into
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REGENERATIVE MEDICINE
the host retinal circuitry [4, 5, 7], as shown in the outer [5]
and inner retina [4, 8, 9].
Current solutions to attenuate the glial response are lim-
ited. Considering the widespread use of MSCs in current ther-
apeutic research, a better understanding of glial responses to
MSC transplantation and the signaling pathways that drive
them is required, particularly with regard to the possible det-
rimental effects of glial cell reactivity. Furthermore, under-
standing of the host glial response following donor cell
transplantation into the eye could be more broadly informa-
tive within the ﬁeld of stem cell regenerative research for the
development of more efﬁcient and successful therapies.
Indeed, reactive gliosis following transplantation is not limited
to MSCs, but it occurs in response to many other donor cell
types, including neuronal cells [9] induced pluripotent cells
[10, 11], Muller stem cells [12], and photoreceptor precursors
[5], transplanted either into the vitreous or in the subretinal
space for regenerative and protective purposes. Moreover,
similar hostile glial responses are not conﬁned to the retina
and the optic nerve but have also been observed in other
part of the CNS, such as in the spinal cord following Schwann
cell transplantation at the site of injury [13].
In this study, retinal glia responses to grafted BM-MSCs
and the associated molecular mechanisms were investigated.
We report for the ﬁrst time the characteristics of the strong
inﬂammatory response that accompanies reactive gliosis fol-
lowing BM-MSC transplantation and we identify LCN2 as an
additional indicator of reactive gliosis in the recipient retina.
Moreover, we suggest the MAPK and JAK/STAT3 cascades in
Muller cells are central mechanisms orchestrating glial and
inﬂammatory responses to donor BM-MSCs.
MATERIALS AND METHODS
Animals
C57BL/6 mice (6–8 weeks old) were purchased from Charles
River, Ltd. (Kent, U.K., http://www.criver.com). Hes5-GFP
transgenic mice were provided by Prof. Verdon Taylor (Univer-
sity of Basel, Switzerland). Glial ﬁbrillary acidic protein (GFAP)-
STAT3-cKO mice were donated Prof. Michael Sofroniew
(UCLA). All procedures were carried out in accordance with
U.K. Home Ofﬁce regulation for the care and use of labora-
tory animals and the U.K. Animals (Scientiﬁc Procedures) Act
(1986).
Cell Culture
The C57BL/6 mouse GFP1ve BM-MSC (Cyagen Biosciences,
Inc., Sunnyvale, CA, http://www.cyagen.com/us/en/), MIO-M1
(donated by Prof. Astrid Limb, UCL, London, U.K.), and Fibro-
blast NIH3T3 cell line (Cell Biolabs, Inc., San Diego, CA,
www.cellbiolabs.com) were cultured in Dulbecco’s modiﬁed
Eagle’s medium, 10% fetal bovine serum penicillin (100 U/ml),
and streptomycin (100 mg/ml) at 378C and 5% CO2 (all compo-
nents from Life Technologies, Leicestershire, U.K., https://
www.lifetechnologies.com). Mouse neural precursor cells
(NPCs), donated by Dr. Stefano Pluchino (University of Cam-
bridge, U.K.), were prepared and cultured as described [14].
Intravitreal Stem Cell Transplantation
Mice (n5 5) were anesthetized and eyes were treated with
topical administration of tetracaine hydrochloride 0.5% and
tropicamide. Intravitreal injections (2 ml) of Zymosan or stem
cells (10,000 cells per microliter) were performed with a 33
Gauge needle (Hamilton, Co., Reno, NV; http://www.hamilton-
company.com) on a 5 ml syringe (Hamilton, Co., http://www.
hamiltoncompany.com). Phosphate buffered saline (PBS) sham
control injection was performed in the right eye. Animals
were culled 7 days after transplantation.
EdU Proliferation Assay
One day before sacriﬁce, animals (n5 3) were intraperitone-
ally injected with 50 mg/kg of EdU (5-ethynyl-20-deoxyuridine,
Life Technologies, Leicestershire, U.K., https://www.lifetechnol-
ogies.com). In in vitro assays, EdU (10 mg/ml) was added to
the medium 3 hours before cell ﬁxation. EdU labeling was
conducted using Click-iT EdU Alexa Fluor 555 Imaging Kit
according to the manufacturer’s protocol.
Proteome Profiler Array
The mouse cytokine array (R&D System, Abingdon, U.K.,
https://www.rndsystems.com) was used according to manufac-
turer’s protocol. Retinal lysate membranes (n5 4) were devel-
oped using the ECL Prime Detection Reagent (Amersham, GE
Healthcare, Little Chalfont, U.K., http://www3.gehealthcare.co.
uk) and quantiﬁcation by band densitometry using ImageJ.
Muller Cell Isolation
Hes5-GFP1ve retinas were dissociated in a single-cell suspension
by 7-minute incubation in 0.1% trypsin (Sigma-Aldrich, Corp.,
Cambridge, U.K., https://www.sigmaaldrich.com/united-king-
dom.html) at 378C. DNase 0.01% (D5025-15 ku, Sigma-Aldrich,
Corp., Cambridge, U.K., https://www.sigmaaldrich.com/united-
kingdom.html) was added to the sample followed by centrifu-
gation at 600g for 5 minutes. The pellet was resuspended in
Mg21/Ca21-free Hanks’ balanced saline solution (Life Technolo-
gies), containing 1% bovin serum albumin (BSA) (Sigma-Aldrich,
Corp., Cambridge, U.K., https://www.sigmaaldrich.com/united-
kingdom.html), 0.05% trypsin inhibitor (Sigma-Aldrich, Corp.,
Cambridge, U.K., https://www.sigmaaldrich.com/united-kingdom.
html), and 0.002% DNase. Samples were centrifuged and resus-
pended in 1% BSA at a density of 107 cells per milliliter.
GFP1ve cells were sorted and collected in RNeasy Lysis Buffer
(RLT) buffer for RNA extraction. Purity of ﬂuorescence-
activated cell sorted (FACS) Muller cells was assessed by
Power Syber Green RNA to Ct-1 step kit (Applied Biosystems,
Leicestershire, U.K., https://www.lifetechnologies.com) acc-
ording to manufacturer’s instructions. Primer sequences
used in both these assays are listed in Supporting Information
Table S1.
Microarray Gene Expression Profiling
Retinal total RNA (na€ıve control n5 4; Zymosan, PBS, MSC
injected n5 5) was extracted using the RNeasy micro kit (Qia-
gen, Manchester, U.K., https://www.qiagen.com) according to
manufacturer’s instructions. Genomic DNA was removed by
DNase (Qiagen, Manchester, U.K., https://www.qiagen.com)
treatment. RNA samples were ampliﬁed using the TotalPrep
Ampliﬁcation Kit (Applied Biosystems, Leicestershire, U.K.,
Tassoni, Gutteridge, Barber et al. 3007
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https://www.lifetechnologies.com). Biotin-labeled cRNA (1.5
mg) was hybridized on the Illumina mouse WG-6 v2.0
Expression Beadchip at 558C for 18 hours. Hybridized Bead-
Chips were then labeled with streptavidin-Cy3 and scanned
with the Illumina BeadStation 500 system. Microarray data
were quantile normalized and log 2 transformed prior to
analysis.
Quantitative RT-PCR
Total RNA (na€ıve control n5 4; Zymosan, PBS, MSC injected
n5 5) was reverse-transcribed into cDNA using a High
Capacity RNA to cDNA kit (Life Technologies, Leicestershire,
U.K., https://www.lifetechnologies.com) according to manu-
facturer’s instructions. Real-time PCR was performed using
TaqMan Gene Expression PCR Master mix (Applied Biosys-
tems Leicestershire, U.K., https://www.lifetechnologies.
com). All selected assays are listed in Supporting Informa-
tion Table S1.
Western Blot
Retinas (na€ıve control n5 4; Zymosan, PBS, MSC injected
n5 5) were homogenized mechanically in lysis buffer (Roche,
West Sussex, U.K., https://www.roche.co.uk) containing a pro-
tease inhibitor EDTA-free tablet (Roche, West Sussex, U.K.,
https://www.roche.co.uk) and phosphatase inhibitor cocktail
(Thermo Scientiﬁc, Loughborough, U.K., http://www.thermo-
scientiﬁc.com/en/home.html). Protein samples were run on
precast gels (Life Technologies, Leicestershire, U.K., https://www.
lifetechnologies.com) and electrotransferred to polyvnylidene
Diﬂuoride (PVDF) membranes (Life Technologies, Leicestershire,
U.K., https://www.lifetechnologies.com). PVDF membranes were
blocked in PBST (5% dried skimmed milk, in 0.1 M PBS 0.2%
Tween 20 (Sigma-Aldrich, Corp., Cambridge, U.K., https://www.
sigmaaldrich.com/united-kingdom.html) at room temperature
(RT) for 1 hour, incubated overnight with primary antibody at
48C and for 1 hour at RT with secondary antibody horseradish
peroxidase (HRP) conjugated. Signal was developed using the
ECL Prime Detection Reagent (Amersham, GE Healthcare, Little
Chalfont, U.K., http://www3.gehealthcare.co.uk).
Retinal Explant Culture
Retinal tissue was obtained from healthy adult mice as previ-
ously described [15]. The isolated retina (control n5 4;
treated n5 5) was cut into four equal-sized explants, placed
on 12-mm diameter ﬁlters (0.4 mm pore, Millipore, Watford,
U.K., http://www.merck.co.uk/en/index.html) with the RGC
side up and cultured in Neurobasal-A medium, supplemented
with B27 (2%), N2 (1%), L-glutamine (0.8 mM), penicillin (100
U/ml), and streptomycin (100 mg/ml) (all components from
Life Technologies, Inc., Leicestershire, U.K., https://www.life-
technologies.com). For coculture experiments, 1 ml of stem
cell suspension (750 cells per microliter) was added to the
RGC surface on day ex vivo (DEV) 1 and maintained for 5
days at 358C and 5% CO2.
Immunohistochemistry
Retinal explant tissue was processed for immunohistochemis-
try as previously described [16]. Tissue sections were
blocked in PBS containing 4% normal goat serum (Life Tech-
nologies, Inc., Leicestershire, U.K., https://www.lifetechnolo-
gies.com) and 0.3% Triton X-100 (Sigma-Aldrich, Corp.) for
1 hour, followed by incubation overnight at 48C with pri-
mary antibody (Supporting Information Table S2) and with
the appropriate AlexaFluor-conjugated secondary antibody for
2 hours at RT the following day. Nuclei were counterstained
with 4,6-diamidino-2-phenylindole (Life Technologies, Inc.,
Leicestershire, U.K., https://www.lifetechnologies.com). Images
were processed using Leica software (LAS AF V2.6.0 Leica
Microsystems GmbH) and Image J.
Statistics
Data shown are the mean6 SEM. Statistical analysis was per-
formed with GraphPad Prism using the unpaired Student’s t
test, two-way, or one-way ANOVA with Bonferroni or Tukey’s
post hoc test. For microarray analysis, data were quantile nor-
malized and log 2 transformed prior to analysis. Probes
detected in fewer than three samples (Illumina detection
p< .05) were also discarded. All analysis was conducted in R/
Bioconductor [17]. Principal components analysis was per-
formed using the pcaMethods package [18]. Differential
expression analysis was performed using limma [19] and gene
set enrichment analysis by camera [20] using gene ontology
(GO) annotations [21].
RESULTS
BM-MSC Transplantation Induces Extensive Reactive
Gliosis and Inflammation in the Host Retina
Reactive gliosis has been reported to be a major barrier to
effective stem cell transplantation therapy in the retina [4, 5].
As shown by immunohistochemistry at 7 days post-
transplantation, GFAP was highly expressed in the Muller cell
processes throughout the retinal layers of BM-MSC recipient
retinas, while its expression was limited to the astrocytes of
the nerve ﬁber layer in sham control retinas (Fig. 1A). A simi-
lar glial response to transplanted cells was observed both in
vivo and ex vivo using NPCs, MIO-M1 cells, and ﬁbroblasts
(Supporting Information Fig. S1). Using Western blotting, we
examined the temporal proﬁle of the gliotic response follow-
ing BM-MSC transplantation at 1, 3, 7, and 14 days in vivo
(DIV). GFAP expression signiﬁcantly increased at 7DIV (Fig.
1B–1D) and remained elevated for at least 14 days, showing a
2.02-fold (60.17) increase in the host retina compared to PBS
sham control (Fig. 1B). Alongside GFAP, both Nestin and
Vimentin were signiﬁcantly increased at 7DIV post-BM-MSC
transplantation (Fig. 1A, 1C–1F).
Upon BM-MSC transplantation, retinal tissue underwent
structural disorganization characterized by an increase in the
retinal thickness, retinal detachment, and folding of the outer
nuclear layer (Supporting Information Fig. S2A, S2B). Retinal
folding and detachment have previously been reported to be
associated with excessive immune recruitment to the retina
[22] and similar retinal changes can be observed after intravi-
treal injection of Zymosan, a proinﬂammatory mediator (Sup-
porting Information Fig. S2C). We next investigated the
inﬂammatory response following transplantation by measuring
microglial reactivity and macrophage inﬁltration. EdU was
administered intraperitoneally to mice 24 hours prior to sacri-
ﬁce and retinas were double immunolabeled for Iba1 and
EdU (Fig. 1G). In the presence of transplanted BM-MSCs,
Iba11ve cells were mainly distributed in proximity to the graft
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where they displayed a typical reactive hypertrophic pheno-
type. Moreover, the presence of cells positive for both Iba1
and EdU conﬁrmed microglia proliferation in response to
donor BM-MSCs (Fig. 1G, white arrows). Conversely, in sham
control eyes, microglial cells appeared to have a more scat-
tered distribution and displayed the characteristic ramiﬁed
morphology that is typical of microglia in a resting state (Fig.
1G). Microglial activation and macrophage inﬁltration were
assessed using the marker F4/80 alongside Iba1 (Fig. 1G).
Although no double positive labeling was observed within the
retina of mice receiving PBS-sham injections or BM-MSC
transplantation, strong reactivity for both F4/80 and Iba1 was
detected within the BM-MSC graft in the vitreous cavity, sug-
gesting the recruitment of recipient-derived inﬁltrating macro-
phages to the graft (Fig. 1G). To better understand
macrophage chemotaxis induced by transplanted BM-MSCs,
the relative abundance of chemokines and cytokines released
by the retina in response to grafted BM-MSCs was investi-
gated using a mouse cytokine array (Fig. 1H). The monocyte-
macrophage lineage marker CD45 showed a signiﬁcant 6.6-
fold (61.24) increase in the BM-MSC transplanted group,
compared to na€ıve control retina (Fig. 1I). Several chemokines
and cytokines were also increased in response to grafted
BM-MSCs, with CCL2, CCL3, CXCL10, and INFc showing a sig-
niﬁcant increase compared to na€ıve control retina (Fig. 1J,
1K). Results showed that following BM-MSC transplantation,
the host retina undergoes extensive reactive gliosis and
inﬂammation, characterized by upregulation of intermediate
ﬁlaments and blood stream-derived monocyte recruitment.
Gene Expression Profiling of BM-MSC Recipient Retina
We next investigated possible signaling pathways orchestrat-
ing the gliotic and inﬂammatory response in the recipient ret-
ina following transplantation. Four experimental groups were
examined: mice that received (a) intravitreally injected BM-
MSCs; (b) intravitreal PBS injections (sham control); (c) intravi-
treal proinﬂammatory Zymosan injections (positive control);
and (d) na€ıve wild-type retinas that were used as a negative
control. Retinas were processed for gene expression proﬁling
at 7 days postinjection. Principal component analysis was per-
formed as an initial step in the analysis of the microarray to
give an exploratory overview of the data. As observed in the
plot (Supporting Information Fig. S3A), circles representing
gene expression proﬁle of each experimental group (red, tur-
quoise, green, and purples circles indicating naive control, PBS
sham control, BM-MSC injected, and Zymosan injected group,
respectively) cluster together, conﬁrming similar gene expres-
sion proﬁling among biological replicates. Similar expression
proﬁles of na€ıve wild-type and the PBS sham injected controls
conﬁrmed that the surgical procedure did not have any major
effect on the gene expression proﬁle of these samples (red
circles and turquoise circles, respectively). In order to identify
and investigate the response of key signaling pathways follow-
ing BM-MSC transplantation, a GO-based analysis of the
microarray data was performed. GO terms representative of
the JAK STAT and MAPK signaling cascade and their regulatory
pathways were signiﬁcantly enhanced in BM-MSC receiving
samples compared to PBS sham controls (Supporting Informa-
tion Fig. S3B). Interestingly, in addition to the involvement of
both the ERK1–2 and STAT3 signaling cascades, the P53-
mediated apoptotic signaling pathway was also signiﬁcantly
Figure 1. MSC transplantation induces reactive gliosis and inﬂam-
mation in the recipient retina. (A): Immunostaining showing upregula-
tion of the intermediate ﬁlaments (red) GFAP, Vimentin, and Nestin
following transplantation. Scale bar5 200 mm. (B): Time course of
GFAP protein expression in MSC recipient retinas relative to PBS sham
injected retinas (n5 4, two-way ANOVA). (C): Western blot and its
quantiﬁcation (D–F) conﬁrming gliosis at 7 days post-transplantation.
(G): Immunolabeling for Edu and F4/80 (green) with the pan microglia
marker Iba1 (red) showing microglia proliferation (white arrows) and
macrophage recruitment in MSC recipient retina. Scale bar5 100 mm.
(H–K): Proteome proﬁler array and its quantiﬁcation (n5 4 per group).
Black, gray, and white bars represent protein expression level in MSC
recipient-, PBS sham injected-, and na€ıve control retina, respectively.
Error bars represent SEM, *, p< .05, **, p< .01; ***, p< .001, one-
way ANOVA test with Tukey’s correction. Abbreviations: GFAP, glial
ﬁbrillary acidic protein; INL, inner nuclear layer; MSC, mesenchymal
stem cell; ONL, outer nuclear layer; PBS, phosphate buffered saline;
RGCL, retinal ganglion cell layer.
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enriched in retinal samples receiving BM-MSC transplants
(Supporting Information Fig. S3B), suggesting a detrimental
effect mediated by graft-induced gliosis and inﬂammation.
A heat map with the top 25 gene changes was generated
in order to identify the most differentially expressed genes
among the experimental groups. Interestingly, concomitant
with the overexpression of glial and immune related genes,
STAT3 and its endogenous suppressor SOCS3 were also dem-
onstrated to be strongly upregulated in the BM-MSC trans-
plant group, suggesting the involvement of this pathway in
the immune response of the retina to the graft (Fig. 2A, red
arrows). A volcano plot comparing samples from PBS sham
and BM-MSC injected retina was performed in order to give
an overview of genes whose expression altered the most (Fig.
2B). Alongside factors representative of gliotic response and
immune cell recruitment, key members of the STAT3 signaling
pathway, including IL6st, STAT3, and SOCS3, appeared signiﬁ-
cantly induced in retinal samples receiving BM-MSC transplan-
tation (Fig. 2B, purple circles). Moreover, one of the genes
that changed most in expression was the autocrine mediator
of reactive astrocytosis Lipocalin-2 (Lcn2, Fig. 2B, red circle).
Microarray data were validated by qPCR, where highly signiﬁ-
cant induction of glial markers, such as S100a, GFAP, Vimentin,
and Nestin (Fig. 2C) and microglia/macrophage markers Iba1
and Emr1/F480 were observed (Fig. 2D). STAT3 and its
upstream receptor IL6st (Fig. 2D) were also conﬁrmed to be
signiﬁcantly upregulated in BM-MSC recipient retina com-
pared to na€ıve control, with a 6.1- (61.25) and 3.85-fold
(60.19) increase, respectively (Fig. 2E). Strikingly, a signiﬁcant
125-fold (629) induction of Lcn2 was demonstrated in BM-
MSC recipient retina (Fig. 2F, p5 .0007). To assess STAT3 tran-
scriptional activity in the Muller glia cell population, STAT3
induction was investigated in Muller glia isolated from BM-
MSC recipient retinae at 7 days postinjection. Isolation of a
pure population of Muller cells was achieved by FACS of reti-
nal cells from adult Hes5-GFP1ve mice. In these mice, green
ﬂuorescent protein (GFP) expression, driven by the Hes5 pro-
moter, is lost during development and is restricted to mature
Muller cells during adulthood (Supporting Information Fig.
S4Ai–S4Aiii). The purity and identity of the sorted Hes5-
Figure 2. Microarray gene expression proﬁling of MSC recipient retina. (A): The top 25 probes showing the most signiﬁcant changes in
gene expression as ranked by ANOVA p-value over the control (CN), sham (PBS), and MSC-treated (MSC) groups. The expression levels
of each probe across the three treatment groups are mean-centered and are shown alongside the gene they map to. Red means high
expression and blue means low expression compared to the average expression across the samples. Components of the STAT3 signaling
are highlighted (red arrows). (B): Volcano plot showing key marker genes in retinal samples receiving MSC transplantation compared to
PBS injected control groups. Key genes known to be markers of macrophage chemoattractant (green triangles), glial cells (red triangles),
and STAT3 signaling (purple triangles) are highlighted. (C–F): Validation of the microarray data by qPCR. Error bars represent SEM, **,
p< .01; ***, p< .001, one-way ANOVA test with Tukey’s correction. Abbreviations: CN, control; GFAP, glial ﬁbrillary acidic protein; MSC,
mesenchymal stem cell; PBS, phosphate buffered saline.
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GFP1ve cell population were conﬁrmed by assessing the
expression of marker speciﬁc for neurons (Thy1 and NeuN),
photoreceptors (Recoverin Rcv), astrocytes (GFAP), microglia
(Iba1), and Muller glia (Vimentin and GFP) by PCR (Support-
ing Information Fig. S4B). Although a weak signal in Recoverin
expression was observed, suggestive of the presence of pho-
toreceptors contamination in the sorted cell population (Sup-
porting Information Fig. S4B), the level of contamination was
judged to be negligible. The gene expression level of Rcv and
GFP in na€ıve retina and sorted Hes5-GFP1ve Muller cells was
quantiﬁed and plotted in the bar graph in Supporting Infor-
mation Figure S4C as percentage of expression relative to
Gapdh. As reported, in na€ıve total retina the GFP and Rcv
gene expression represented 0.47%6 0.04% and 5.6%6 1%
of Gapdh expression, respectively. After sorting, in the Hes5-
GFP1ve cell population, the percentage of Rcv gene expres-
sion was reduced to 0.28%6 0.1% of Gapdh expression, com-
pared to the percentage of GFP expression, which increased
to 20.23%6 3.7% relative to Gapdh (Supporting Information
Fig. S4C, white and black bars, respectively). Using this puri-
ﬁed population of Hes5-GFP1ve Muller cells, gene expression
was investigated by qPCR, conﬁrming a 13.89- (62.96),
38.93- (62.13), and 2.21-fold (60.06) increase in GFAP, LCN2,
and STAT3 gene expression, respectively, in Muller cells
following BM-MSC transplantation (Supporting Information
Fig. S4D–S4F).
BM-MSC Transplantation Results in LCN2 Production
and Activation of STAT3 and ERK in Retinal Muller Glia
In the canonical JAK/STAT pathway, STAT3 activation involves
phosphorylation of STAT3 on its tyrosine (Y705 p-STAT3) resi-
due [23]. As assessed by Western blot at 7DIV (Fig. 3Ai),
alongside GFAP upregulation, the total protein expression
level of STAT3, as well as its phosphorylated state, was
remarkably high in the BM-MSC treatment group compared
to the control and sham group, with phospho-STAT3 showing
a highly signiﬁcant increase of 8.98-fold (61.5, p val-
ue5 .0011) in retinas receiving GFP1ve BM-MSC transplants
(Fig. 3Aii). Double immunolabeling for the Muller glia marker
glutamine synthetase (GS) and p-STAT3 conﬁrmed activation
of STAT3 in retinal Muller cells following transplantation (Fig.
3Aiii–3Av, green and red, respectively).
The microarray data also highlighted that the MAPK cas-
cades, ERK1–2 and stress-activated JNK, were among the most
responsive pathways to BM-MSC transplantation. MAPKs are
serine/threonine kinases able to orchestrate cellular responses
activating transcription factors by phosphorylation, for exam-
ple, phosphorylating STAT3 on the Serine residue 727 [24].
Maximal transcriptional activity of STAT3 is achieved when
STAT3 is phosphorylated on both tyrosine 705 and serine 727
[25]. To validate MAPK cascade activation, phosphorylation/
activation of ERK1-2 was examined and quantiﬁed by Western
blot (Fig. 3Bi), showing a highly signiﬁcant 10.71-fold (60.49,
p< .001) increase following BM-MSC transplantation (Fig.
3Biii). Alongside ERK-1/2, activation of the stress-activated
JNK cascade was also conﬁrmed (Fig. 3Bii), with JNK phospho-
rylation level undergoing a signiﬁcant 24.51-fold (62.44, p
value5 .001) increase compared to na€ıve controls (Fig. 3Biv).
This was accompanied by a signiﬁcant 5.43-fold (60.93)
increase in the phosphorylation on Ser 727 of STAT3 (Fig.
3Bv). Double immunolabeling for GS and phospho-ERK1/2
Figure 3. MSC transplantation results in LCN2 production and
STAT3 and ERK activation in retinal Muller glia. Immunostaining
and Western blot conﬁrming activation of (A) JAK STAT cascade,
(B) MAPK cascade, and (C) LCN2 in retinal Muller glia following
MSC transplantation. Error bars represent SEM, *, p< .05; **,
p< .01; ***, p< .001, one-way ANOVA test with Tukey’s correc-
tion. Abbreviations: GFAP, glial ﬁbrillary acidic protein; GFP, green
ﬂuorescent protein; INL, inner nuclear layer; MSC, mesenchymal
stem cell; ONL, outer nuclear layer; PBS, phosphate buffered
saline; RGCL, retinal ganglion cell layer.
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conﬁrmed activation of ERK1/2 in BM-MSC recipient retinal
Muller glia (Fig. 3Bvi–3Bviii, blue and red, respectively).
LCN2 was seen to be one of the most differentially
expressed genes within the BM-MSC recipient retina. An
increase in the protein expression level of LCN2 at 7 DIV post-
transplantation was conﬁrmed by Western blot (Fig. 3Ci),
showing a 15.95-fold (64.1, p value5 .009) increase in BM-
MSC transplanted retinas compared to na€ıve controls (Fig.
3Cii). Double immunolabeling of BM-MSC transplanted retinal
sections for the Muller glial marker GS and LCN2 conﬁrmed
LCN2 expression by Muller cells (Fig. 3Ciii–3Cv, blue and red,
respectively). There is wealth of evidence that in response to
upstream cytokines and growth factors, including IL6, CNTF,
IL1b, and PDGF, both JAK and MAPK kinases induce STAT3
transcriptional activity by phosphorylating STAT3 on its tyro-
sine 705 and serine 727 residue, respectively [23, 26]. Phos-
phorylated STAT3 dimers migrate into the nucleus and
transcribe target genes, such as GFAP [27] and CxCl10 [28].
These results conﬁrm that following BM-MSC transplantation,
the downstream effector of MAPK and JAK/STAT pathways
STAT3 is signiﬁcantly upregulated in retinal Muller glia. Such
induction coincided with a remarkable increase in both LCN2
and GFAP gene expression level in isolated Muller cells, most
likely induced by ERK1–2 [29] and STAT3 [27].
Retinal Glia Undergo Reactive Gliosis Via a STAT3-
Dependent Mechanism Ex Vivo Which Limits Retinal
Engraftment of Stem Cells
The retinal explant organotypic culture system is an ex vivo
model previously developed in our lab as a screening tool for
neuroprotective therapies [15, 16]. Here, we used the same
model to test the efﬁciency of selected drugs in modulating
glial reactivity following coculture with BM-MSCs. For this pur-
pose, GFP1ve BM-MSCs were cocultured on the inner surface
of retinal explants for 4DEV. We ﬁrst investigated whether the
retinal organotypic culture system recapitulates the in vivo
response to grafted BM-MSCs. Similarly to what was observed
in vivo, at 4DEV retinal explants undergo upregulation of
GFAP and phosphorylation of STAT3 in the inner nuclear layer
in presence of cocultured BM-MSCs (Fig. 4A, 4B). In order to
assess whether STAT3 plays a central role in graft-mediated
reactive gliosis in the explant system, we investigated the
effect of pharmacological inhibition of STAT3 on GFAP overex-
pression following BM-MSC coculture. Different doses of
STAT3 inhibitor VI (S31–201) were tested; STAT3 inhibition at
80 and 100 mM successfully suppressed GFAP expression com-
pared to vehicle treated samples (Fig. 4Ci–4Ciii). Interestingly,
GFAP suppression mediated by the STAT3 inhibitor (100 mM)
was accompanied by a signiﬁcant increase of 4.8-fold (61.01)
in the number of GFP1ve BM-MSCs inﬁltrating the host retinal
layers, in comparison to control retinal explants where BM-
MSC migration within the tissue was very rare (Fig. 4Ciii,
4Cvi). Double immunoﬂuorescence for phosphorylated STAT3
and the Muller glia marker GS conﬁrmed inhibition of STAT3
in explants receiving the pharmacological agents (Fig. 4Civ,
4Cv). STAT3 inhibition did not affect neuronal survival and
expression of the other intermediate ﬁlaments, vimentin and
nestin (Supporting Information Fig. S5).
In order to conﬁrm the central role of STAT3 in retinal
Muller cell gliosis induced by grafted BM-MSCs, retinal GFAP
expression following coculture with BM-MSCs was explored in
retinal explants obtained from GFAP-STAT3 conditional knock-
out mice (GFAP-STAT3-cKO), where conditional deletion of
STAT3 from GFAP expressing cells was achieved using the Cre/
loxP system [30]. Unlike wild-type retinal explants, STAT3cKO
retinal explants cocultured with BM-MSC did not show any
increase in GFAP expression (Fig. 4Di–4Div). In addition, small
numbers of BM-MSCs were found within the host tissue (Fig.
4Div).
Finally, the role of STAT3 in GFAP overexpression following
BM-MSC transplantation was investigated in vivo using GFAP-
STAT3 cKO mice in comparison to wild-type control animals.
The overall expression of GFAP in Muller cells processes fol-
lowing PBS sham injection was reduced in cKO mice com-
pared to WT retinas (Fig. 4D compare v with vi); however,
cKO retinas did still show some upregulation of GFAP in
response to transplanted BM-MSCs (Fig. 4D compare vi with
viii).
The observation that GFAP upregulation via STAT-3-
dependent mechanisms is less marked in vivo than ex vivo
suggests that in vivo other pathways beside STAT3 contribute
to reactive gliosis. Therefore, we questioned whether LCN2
and ERK1/2, highly induced in vivo following BM-MSC trans-
plantation, were also upregulated in the retinal explants sys-
tem. Surprisingly, neither activation of ERK1/2 nor increase in
LCN2 protein expression level was observed in the presence
of cocultured BM-MSCs (Supporting Information Fig. S6). We
therefore hypothesize that an important role might be played
in vivo by recruited macrophages, whose role in glial activa-
tion and chronic inﬂammation is undetectable in an isolated
system such as the retinal explant organotypic culture.
DISCUSSION
To date, the evidence of structural and functional beneﬁts
offered by transplanted MSCs to neurons in animal models of
neurodegenerative conditions is very encouraging [31–33] and
many clinical trials have been investigating the safety and efﬁ-
cacy of MSCs in a variety of neurodegenerative diseases, with
promising preliminary results [34–36]. As we recently pub-
lished [2] in a rat model of glaucoma, transplantation of BM-
MSCs into the vitreous body resulted in a signiﬁcant 30%
increase in optic nerve axonal survival, supporting further
investigation of the use of MSCs for neuroprotective pur-
poses. Although neuroprotective strategies will not rescue
dead RGCs, neuroprotection could conceivably slow down the
progressive deterioration that many patients experience over
the course of their disease. Moreover, rudimentary reconnec-
tion resulting from some level of plasticity achieved by stem
cell-based strategies might potentially be beneﬁcial to
patients with advanced visual loss.
However, despite the beneﬁts conferred by MSCs to axo-
nal survival, one of the major limitations that still needs to be
overcome is the extensive reactive gliosis occurring in the
recipient retina following MSC transplantation [4, 6]. Reactive
gliosis represents a barrier to successful stem cell-based strat-
egies in several neuropathological conditions [4, 5, 13, 37,
38]. In an animal model of retinal degeneration both subreti-
nal and intravitreal stem cell transplantation resulted in strong
reactive gliosis and chondroitin sulfate proteoglycan deposi-
tion limiting stem cell migration into the host tissue [4, 5, 8,
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Figure 4. STAT3 as a central player in graft-induced reactive gliosis ex vivo but not in vivo. (A, B): Immunostaining showing GFAP over-
expression and STAT3 phosphorylation in retinal explants cocultured with MSC at 4 days ex vivo. (C): Immunostaining showing the effect
of S31–201 in suppressing GFAP expression (i–iii), increasing MSC engraftment (ii, vi), and inhibiting STAT3 phosphorylation (iv, v). (D):
Immunostaining showing that GFAP overexpression induced by donor MSCs is suppressed in GFAP-STAT3 cKO mice ex vivo (i–iv) but not
in vivo (vi–viii); n5 3 per group. Scale bar5 100 mm. Error bars represent SEM, *, p< .05; **, p< .01. Abbreviations: GFAP, glial ﬁbril-
lary acidic protein; GFP, green ﬂuorescent protein; INL, inner nuclear layer; MSC, mesenchymal stem cell; ONL, outer nuclear layer; PBS,
phosphate buffered saline; RGCL, retinal ganglion cell layer.
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12]. This effect appeared to be independent of the type and
origin of stem cells transplanted and, consistent with our
study, was observed with both heterologous and autologous
stem cell sources including Muller stem cells [12], photorecep-
tor precursors [5], neuronal progenitors [9], induced pluripo-
tent stem cells [10, 11], and MSCs [4, 39]. Here, we offer a
detailed investigation of retina glial responses to intravitreal
BM-MSC transplantation in order to identify molecular mech-
anisms behind graft-induced reactive gliosis in the retina.
We observed that following BM-MSC transplantation
recipient retina undergoes GFAP overexpression, extensive
macrophage inﬁltration, and retinal folding and detachment.
These responses were accompanied by activation of JAK/
STAT3 and MAPK cascade and marked production of LCN2 by
Muller glia. Using gene expression proﬁling, we identiﬁed
LCN2, with a 125-fold induction in gene expression in BM-
MSC recipient retina, as a potential new marker of retinal
reactive gliosis. There is increasing evidence correlating
astrocyte-mediated LCN2 secretion to neuroinﬂammation [28,
40], reactive gliosis [41], and neuronal death [40]. Although
the mechanism through which LCN2 signals is not yet clear,
its expression has been reported to be mediated by the
ERK1/2 and INFc/STAT1 signaling cascade [29]. Moreover, in
different models of neurodegeneration, LCN2 acts as chemo-
kine inducer by promoting the upregulation of chemokines,
such as CCL2 and CXCL10, through the JAK2/STAT3 pathway
[28]. There is evidence that under degenerative conditions
reactive astrocyte gain neurotoxic properties and recent stud-
ies have identiﬁed LCN2 as an inducible neurotoxic mediator
secreted by astrocytes to promote neuronal death [40]. Based
on this evidence, LCN2 secretion in the host retina following
BM-MSC transplantation suggests a potential detrimental glial
response that needs to be modulated.
Here, we propose a molecular mechanism orchestrating
graft-induced-retinal reactive gliosis in the retina. As depicted
in the diagram shown in Figure 5 (signaling 1) intravitreally
transplanted BM-MSCs secrete factors, including CNTF and IL6
[3, 42], known to activate the JAK2/STAT3 cascade [3]. Once
activated, STAT3 mediates GFAP upregulation, as observed in
our study and demonstrated previously [27, 30]. According to
recent studies [28], activated STAT3 is also involved in secre-
tion of chemokines such as CCL2–3 and CXCL-10, found to be
highly upregulated in retinal tissue in response to BM-MSC
transplantation. Chemokines play a central role in macrophage
recruitment. Activated macrophages invading the graft can
secrete factors such as INFc, IL-1b, and IL6 which contribute
to MAPK cascade activation [43] (signaling 2). This is sup-
ported by the evidence in our study that recipient retinas
undergo MAPK activation in presence of BM-MSCs in vivo but
not in the macrophage-free ex vivo system. The MAPK cas-
cade may lead to further chemokine secretion [44], GFAP
expression through the AP1/CREB complex [45, 46], and LCN2
expression [29], which we found to be signiﬁcantly upregu-
lated in the host retina in vivo but not ex vivo. Thus, we pro-
pose that LCN2 plays a central role in maintaining reactive
gliosis [41] and neuroinﬂammation [28].
This proposed mechanism could explain why in STAT3
cKO animals in vivo we still observe some GFAP upregula-
tion, in contrast to what we observed in retinal explants.
One of the main differences between ex vivo and in vivo
Figure 5. Schematic diagram depicting a possible molecular mechanism orchestrating retinal gliosis and neuro-inﬂammation in
response to donor MSCs. Abbreviations: GFAP, glial ﬁbrillary acidic protein; MSC, mesenchymal stem cell.
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models is the absence of monocyte/macrophage inﬁltration
ex vivo. In this case, it is likely that GFAP upregulation would
be mediated solely by the JAK/STAT3 cascade potentially ini-
tiated by BM-MSC-secreted CNTF and IL6 (Fig. 5, signaling
2). The lack of a compensatory molecular pathway mediated
by macrophage-induced MAPK activation and LCN2 secretion
(Fig. 5, signaling 2) could explain why ex vivo but not in
vivo, knocking down STAT3 prevents retinal explants from
upregulating GFAP. This is supported by our ﬁndings, where
ex vivo the presence of donor BM-MSCs cocultured on top
of the retinal tissue is accompanied neither by ERK activa-
tion or by LCN2 (Supporting Information Fig. S6). Future
studies will investigate the role of the proposed mechanism
in BM-MSC-induced reactive gliosis in an animal model of
experimental glaucoma in order to ensure that dampening
down Muller glial response to grafted cells does not prevent
BM-MSC-mediated neuroprotection.
CONCLUSIONS
Our proposed mechanism provides a novel platform for fur-
ther investigation into methods to attenuate recipient glial
activation following cell transplantation. So far, neuroprotec-
tion appears a promising approach to enhance RGC survival
and preservation of vision and may be more readily translat-
able to the clinic compared to RGC replacement or regenera-
tion. However, the long-term effects of reactive gliosis and its
modulation need to be better understood before MSC trans-
plantation could be considered as a potential neuroprotective
therapy. Given that the retina and the optic nerve are part of
the CNS, we suggest our ﬁndings may give some insights into
mechanisms behind glial scar-like barrier formation in
response to transplanted cells potentially relevant to other
parts of the CNS.
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